Victory Capital Management Inc Cellectar Biosciences, Inc. Transaction History

Victory Capital Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 07, 2020	SELL	$10.3 - $17.3 $15,089 - $25,344	-1,465 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$11.0 - $31.7 $550 - $1,585	-50 Reduced 3.3%	1,465 $2,000
Q4 2019 Feb 04, 2020	BUY	$10.6 - $24.1 $2,374 - $5,398	224 Added 17.35%	1,515 $4,000
Q3 2019 Nov 12, 2019	BUY	$20.0 - $24.6 $25,820 - $31,758	1,291 New	1,291 $3,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $12.4M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.